While increased blood vessel density and angiogenesis may suggest that individuals with obesity could be candidates for anti-angiogenic therapeutics, breast cancer patients with obesity treated with anti-VEGF antibodies were less sensitive to anti-VEGF treatment due to increased systemic concentrations of IL-6 and FGF-2, which compensated for VEGF inhibition [224]. The gene discussed is VEGFA; the disease is obesity due to melanocortin 4 receptor deficiency.